The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Zimmer Biomet Holdings Inc’s stock clocked out at $88.73, up 0.26% from its previous closing price of $88.5. In other words, the price has increased by $0.26 from its previous closing price. On the day, 3.07 million shares were traded. ZBH stock price reached its highest trading level at $88.94 during the session, while it also had its lowest trading level at $86.51.
Ratios:
To gain a deeper understanding of ZBH’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.60 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.57. For the most recent quarter (mrq), Quick Ratio is recorded 1.39 and its Current Ratio is at 2.43. In the meantime, Its Debt-to-Equity ratio is 0.64 whereas as Long-Term Debt/Eq ratio is at 0.59.
On September 18, 2025, Rothschild & Co Redburn started tracking the stock assigning a Buy rating and target price of $130.
Roth Capital Upgraded its Neutral to Buy on July 15, 2025, while the target price for the stock was maintained at $135.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 11 ’25 when Yi Sang sold 1,200 shares for $103.58 per share. The transaction valued at 124,302 led to the insider holds 18,584 shares of the business.
Yi Sang bought 1,200 shares of ZBH for $124,302 on Sep 11 ’25. On Sep 08 ’25, another insider, Winkler Lori, who serves as the SVP and CHRO of the company, sold 1,500 shares for $104.15 each. As a result, the insider received 156,225 and left with 6,833 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZBH now has a Market Capitalization of 17584650240 and an Enterprise Value of 24525049856. As of this moment, Zimmer’s Price-to-Earnings (P/E) ratio for their current fiscal year is 21.96, and their Forward P/E ratio for the next fiscal year is 10.42. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.89. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.20 while its Price-to-Book (P/B) ratio in mrq is 1.38. Its current Enterprise Value per Revenue stands at 3.061 whereas that against EBITDA is 9.288.
Stock Price History:
The Beta on a monthly basis for ZBH is 0.64, which has changed by -0.19292343 over the last 52 weeks, in comparison to a change of 0.14178503 over the same period for the S&P500. Over the past 52 weeks, ZBH has reached a high of $114.72, while it has fallen to a 52-week low of $85.33. The 50-Day Moving Average of the stock is -11.09%, while the 200-Day Moving Average is calculated to be -11.33%.
Shares Statistics:
It appears that ZBH traded 1.58M shares on average per day over the past three months and 3040730 shares per day over the past ten days. A total of 198.20M shares are outstanding, with a floating share count of 197.91M. Insiders hold about 0.14% of the company’s shares, while institutions hold 101.34% stake in the company. Shares short for ZBH as of 1760486400 were 7137828 with a Short Ratio of 4.53, compared to 1757894400 on 6572390. Therefore, it implies a Short% of Shares Outstanding of 7137828 and a Short% of Float of 4.1300002000000005.
Dividends & Splits
With its trailing 12-month dividend rate of 0.96, ZBH has a forward annual dividend rate of 0.96. Against a Trailing Annual Dividend Yield of 0.010847458. The stock’s 5-year Average Dividend Yield is 0.79. The current Payout Ratio is 21.66% for ZBH, which recently paid a dividend on 2025-09-30 with an ex-dividend date of 2025-09-30. Stock splits for the company last occurred on 2022-03-01 when the company split stock in a 103:100 ratio.
Earnings Estimates
A detailed examination of Zimmer Biomet Holdings Inc (ZBH) is currently in progress, with 25.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $1.92, with high estimates of $2.09 and low estimates of $1.78.
Analysts are recommending an EPS of between $8.23 and $7.95 for the fiscal current year, implying an average EPS of $8.16. EPS for the following year is $8.52, with 27.0 analysts recommending between $8.98 and $8.38.
Revenue Estimates
In. The current quarter, 24 analysts expect revenue to total $2.22B. It ranges from a high estimate of $2.24B to a low estimate of $2.21B. As of. The current estimate, Zimmer Biomet Holdings Inc’s year-ago sales were $2.02BFor the next quarter, 24 analysts are estimating revenue of $2.07B. There is a high estimate of $2.12B for the next quarter, whereas the lowest estimate is $1.99B.
A total of 27 analysts have provided revenue estimates for ZBH’s current fiscal year. The highest revenue estimate was $8.23B, while the lowest revenue estimate was $8.16B, resulting in an average revenue estimate of $8.21B. In the same quarter a year ago, actual revenue was $7.68BBased on 26 analysts’ estimates, the company’s revenue will be $8.63B in the next fiscal year. The high estimate is $8.75B and the low estimate is $8.34B.
